In looking at RCE previous posts, and considering the Pasteur...

First 17 Last

Share
Profile

Follow
benluke9

38 Posts.

7

27/03/23

13:18

Post #: 66975702
Share

Originally posted by reon1: ↑

Thanks Red! Great to get some feedback and appreciate your number crunching.

I agree, it would potentially be a big sacrifice once sales momentum picks up. But it could also, from the day of FDA approval, provide a huge boost to marketing and R&D to increase sales to rest-of-world.

I've put some numbers into a spreadsheet:

A note about my assumptions. I've used total sepsis cases because I believe there is a case for using 327 in every case of sepsis due to the rapid decline in survival if treatment is delayed to await antibiogram results. This may change in future with rapidly improving diagnostic technologies. For UTI and burns I've assumed that 327 treatment would be delayed until a 'superbug' has been diagnosed (or failed to respond to conventional antibiotics) and so have used a very rough ~8% UTI's and ~15% burns.

So I agree, with modest pricing and market uptake, sales could quickly and dramatically exceed that of a PASTEUR contract.

But what if the topical product, under it's own separate brand name, could secure a contract? This could provide some early cash flow to hit the ground running, helping to fund marketing and R&D of other products, without sacrificing a huge sales potential in the USA.

If anyone has done any crude modelling of sales, please share.

Expand

In looking at RCE previous posts, and considering the Pasteur act has the potential to assist with security of future funding, Tuberculosis is yet another bacteria that is a likely candidate.

But like sepsis, it has a high cost to treat, possibly more than sepsis, maybe simpler to administer and potentially a smaller market for the risk/reward for RCE.

that is if the inhalant is successful.

I like the multiple fronts RCE has, is Pursuing and with IP on manufacturing, surely would limit potential competition for at the very least 10 years.

RCE Price at posting: 57.0¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply